87 completed. 87 Phase 2, 16 Phase 1, 11 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 87 | Completed 87 |
| Phase 1 | 16 | Completed 16 |
| Phase 3 | 11 | Completed 11 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment Mesenchymal Stem Cells from Wharton´s jelly - Systemic Sclerosis Pulmonary, Pulmonary Hypertension | Phase 1 / Phase 2 | Completed | Fundación Neumologica Colombiana | 1 | 2024-05-15 | 2026-04-21 |
| Open Label Extension Study of Brentuximab Vedotin in Early dcSSc Brentuximab vedotin - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 3 | 2024-02-14 | 2026-09-30 |
| A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms Avenciguat (BI 685509), Placebo - Scleroderma, Systemic | Phase 2 | Completed | Boehringer Ingelheim | 214 | 2022-12-13 | 2026-03-17 |
| An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis nemolizumab - Systemic Sclerosis | Phase 2 | Completed | Maruho Co., Ltd. | 6 | 2022-04-20 | 2026-02-13 |
| Rituxmab Versus IL-6 in Treating ILD Rituximab, IL6 inhibitor - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Assiut University | 60 | 2021-12-01 | 2023-11-15 |
| Effects of FT011 in Systemic Sclerosis FT011, Placebo - Scleroderma, Systemic, Scleroderma, Diffuse | Phase 2 | Completed | Certa Therapeutics | 30 | 2021-07-19 | 2023-12-20 |
| A Study of Guselkumab in Participants With Systemic Sclerosis Guselkumab Dose 1, Guselkumab Dose 2, Placebo - Scleroderma, Systemic | Phase 2 | Completed | Janssen Pharmaceutical K.K. | 56 | 2021-02-24 | 2025-07-23 |
| Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis MT-7117, Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | Tanabe Pharma America, Inc. | 76 | 2021-02-05 | 2025-12-30 |
| A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis GS-248, Placebo - Systemic Sclerosis | Phase 2 | Completed | Gesynta Pharma AB | 94 | 2020-12-29 | 2024-08-09 |
| Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue) "ACHIM" as solute (10^9 intestinal microbes/ml) - Systemic Sclerosis | Phase 2 | Completed | Oslo University Hospital | 75 | 2020-09-24 | 2022-10-12 |
| Effects of Fractional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis CO2 Vaginal Laser - Systemic Sclerosis, Vulvovaginal Signs and Symptoms | Phase 2 / Phase 3 | Completed | IRCCS San Raffaele | 16 | 2020-05-01 | 2024-01-30 |
| Cold Challenge With C21 in RP C21, Placebo - Raynaud Phenomenon, Systemic Sclerosis | Phase 2 | Completed | Vicore Pharma AB | 20 | 2020-01-03 | 2023-05-18 |
| Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) IgPro20, IgPro10 - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | CSL Behring | 27 | 2019-09-19 | 2024-02-05 |
| The Benefit of Bermekimab in Patients With Systemic Sclerosis MABp1 (Bermekimab) OR Placebo, MABp1 (Bermekimab) - Scleroderma, Systemic | Phase 2 | Completed | Hellenic Institute for the Study of Sepsis | 20 | 2019-07-19 | 2022-09-29 |
| Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis Brentuximab Vedotin - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 11 | 2019-05-07 | 2023-10-04 |
| Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2) Placebo IV infusion, Iloprost Injection, for intravenous use - Raynaud Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Completed | Civi Biopharma, Inc. | 34 | 2019-03-07 | 2025-05-25 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis GLPG1690, Placebo - Systemic Sclerosis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 33 | 2019-01-14 | 2021-05-04 |
| Gut Microbiota Transplantation in Systemic Sclerosis Anaerobically Cultivated Human Intestinal Microbiota, Anaerobically Cultivated medium - Scleroderma, Systemic | Phase 1 / Phase 2 | Completed | Oslo University Hospital | 10 | 2018-01-18 | 2019-03-13 |
| Prednisolone in Early Diffuse Systemic Sclerosis Prednisolone 5 mg, Placebo oral capsule; From August 2020 'no additional treatment' - Systemic Sclerosis | Phase 2 | Completed | Prof. Ariane herrick | 35 | 2017-12-21 | 2021-07-30 |
| A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis Double-Blind Placebo, Double-Blind Rituximab - Scleroderma, Systemic, Skin Sclerosis | Phase 2 / Phase 3 | Completed | Tokyo University | 56 | 2017-12-04 | 2020-02-18 |
Showing 20 of 87. Sign in to see all of them.
Scleroderma, Diffuse (43) · Raynaud Disease (9) · Lung Diseases, Interstitial (7) · Connective Tissue Diseases (5) · Pulmonary Fibrosis (5) · Autoimmune Diseases (4) · Arthritis (3) · Arthritis, Rheumatoid (2) · Graft vs Host Disease (2) · Hypertension, Pulmonary (2) · Lupus Erythematosus, Systemic (2) · Pain (2) · Rare Diseases (2) · Scleroderma, Limited (2)
Skin and Connective Tissue Diseases (87) · Skin Diseases (85) · Connective Tissue Diseases (82) · Pathological Conditions, Signs and Symptoms (16) · Lung Diseases (14) · Respiratory Tract Diseases (14) · Pathologic Processes (13) · Cardiovascular Diseases (12) · Vascular Diseases (12) · Skin Diseases, Vascular (10) · Embolism and Thrombosis (9) · Livedoid Vasculopathy (9) · Thrombosis (9) · Peripheral Vascular Diseases (8)
Imatinib Mesylate (6) · Mycophenolic Acid (6) · Cyclophosphamide (5) · Rituximab (5) · Bosentan (3) · Brentuximab Vedotin (3) · Abatacept (2) · Antilymphocyte Serum (2) · Methylprednisolone (2) · Nitroglycerin (2) · Stem Cell Transplantation (2) · pirfenidone (2) · riociguat (2) · treprostinil (2) · 5'-palmitoyl cytarabine (1)
Actelion (3) · Assistance Publique - Hôpitaux de Paris (3) · Fred Hutchinson Cancer Center (3) · Hospital for Special Surgery, New York (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Stanford University (3) · Dinesh Khanna, MD, MS (2) · ISDIN (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · MediQuest Therapeutics (2) · Michael Roth (2) · Northwestern University (2) · Oslo University Hospital (2) · Sanofi (2) · University Hospital, Grenoble (2)
United States (47) · United Kingdom (20) · Germany (17) · Italy (13) · France (12) · Canada (11) · Poland (10) · Spain (8) · Belgium (7) · Netherlands (6) · Switzerland (6) · Japan (5) · Australia (4) · Hungary (4) · Mexico (4)
Robert Spiera, MD (3) · Ayumi Yoshizaki, MD, PhD (2) · Daniel E. Furst, MD (2) · Dinesh Khanna, MD (2) · Leona Holmberg (2) · Alexandre WS Silva, PhD (1) · Anna-Maria Hoffmann-Vold, MD, PhD (1) · Anna-Maria Hoffmann-Vold, PhD (1) · Annegret Kuhn, MD (1) · Ariane Herrick, MD (1) · Arnold E. Postlethwaite, MD (1) · Aryeh Fischer, MD (1)
PMID 28298564, PMID 35904231, PMID 11934971, PMID 15692967, PMID 16790698, PMID 17469162, PMID 17485423, PMID 17717203, PMID 17901414, PMID 18512816, PMID 18641099, PMID 19103636, PMID 19180499, PMID 19776222, PMID 19892673, PMID 19950289, PMID 20506355, PMID 20708086, PMID 20740615, PMID 20800376, PMID 21398330, PMID 21769849, PMID 21777972, PMID 23039171, PMID 23118116, PMID 23402088, PMID 23418384, PMID 23494072, PMID 23554239, PMID 24054756, PMID 24459219, PMID 25452309, PMID 25826322, PMID 26071192, PMID 26283632, PMID 26378033, PMID 26724322, PMID 27134280, PMID 27370878, PMID 27463733, PMID 27469583, PMID 28012804, PMID 28038680, PMID 28544580, PMID 28602891, PMID 28619061, PMID 28963118, PMID 29073351, PMID 29099620, PMID 29121645
2016 (2), 2018 (2), 2019 (2), P30CA015704 (2), 1UM1AI110557 (1), 2005 (1), 2008 (1), 2014 (1), R01AI041721 (1), R01AR047219 (1), R01HL089758 (1), R01HL089901 (1), R21AR066305 (1), R34HL122558 (1), U54CA163438 (1)